Urticaria Therapeutics
1. Clarinex patent expiration
Treatment: Treatment of chronic idiopathic urticaria; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis; Treatment of all...
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(6 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US5607697 (Pediatric) | ORGANON | Taste masking microparticles for oral dosage forms |
Dec, 2015
(10 years ago) | |
| US7211582 | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(5 years ago) | |
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US5607697 | ORGANON | Taste masking microparticles for oral dosage forms |
Jun, 2015
(10 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(6 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(4 years ago) | |
|
US7405223 (Pediatric) | ORGANON | Treating allergic and inflammatory conditions |
Jan, 2020
(6 years ago) | |
| US7405223 | ORGANON | Treating allergic and inflammatory conditions |
Jul, 2019
(6 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 14 July, 2005
Dosage: TABLET, ORALLY DISINTEGRATING; TABLET
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
2. Clarinex patent expiration
Treatment: Treatment of allergic rhinitis; Treatment of chronic idiopathic urticaria
CLARINEX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514520 | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Jun, 2018
(7 years ago) | |
| US7214684 | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Dec, 2014
(11 years ago) | |
| US7214683 | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
| US7211582 | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(11 years ago) | |
|
US7214684 (Pediatric) | MERCK SHARP DOHME | Methods for the treatment of allergic rhinitis |
Jun, 2015
(10 years ago) | |
|
US7214683 (Pediatric) | MERCK SHARP DOHME | Compositions of descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US7211582 (Pediatric) | MERCK SHARP DOHME | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(10 years ago) | |
|
US6514520 (Pediatric) | MERCK SHARP DOHME | Stabilized antihistamine syrup |
Dec, 2018
(7 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 01 September, 2004
Dosage: SOLUTION
How can I launch a generic of CLARINEX before it's drug patent expiration?
More Information on Dosage
CLARINEX family patents
3. Rhapsido patent
expiration
Treatment: Treatment of chronic autoimmune urticaria; Treatment of chronic spontaneous urticaria
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512084 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10457647 | NOVARTIS | NA |
Nov, 2034
(8 years from now) | |
| US12419889 | NOVARTIS | NA |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2030 |
Drugs and Companies using REMIBRUTINIB ingredient
NCE-1 date: 30 September, 2029
Market Authorisation Date: 30 September, 2025
Dosage: TABLET
More Information on Dosage
RHAPSIDO family patents